Clinical trial
A Phase I/II Combination Study of Topotecan, Fludarabine, Cytosine Arabinoside and G-CSF (T-FLAG) Induction Therapy in Patients With Poor Prognosis AML, MDS and Relapsed/Refractory ALL Followed by Maintenance of Either PBSC Transplant or 13 Cis-Retinoic Acid
NCT00003619 is registered in ClinicalTrials.gov with Drexel University College of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Combination Study of Topotecan, Fludarabine, Cytosine Arabinoside and G-CSF (T-FLAG) Induction Therapy in Patients With Poor Prognosis AML, MDS and Relapsed/Refractory ALL Followed by Maintenance of Either PBSC Transplant or 13 Cis-Retinoic Acid
- Lead sponsor
- Drexel University College of Medicine
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 28, 1998
- Completion date
- April 30, 2004
- Enrollment
- Not reported
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
chronic myeloproliferative disorders, leukemia, myelodysplastic syndromes, thrombocytopenia